Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy

Epigenomics

Volumn 8, Issue 2, 2016, Pages 285-305

  Katoh, Masaru ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

breast cancer; chronic inflammation; epigenetics; gastric cancer; immune checkpoint blocker; lung cancer; melanoma; MYC; prostate cancer; synthetic lethality

Indexed keywords

ANTINEOPLASTIC AGENT; BRG1 PROTEIN; EI 1; GSK 126; HISTONE METHYLTRANSFERASE; TAZEMETOSTAT; TRANSCRIPTION FACTOR EZH2; UNC 1999; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; MLL3 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; AUTISM; BLADDER CANCER; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DNA METHYLATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FRAMESHIFT MUTATION; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HISTONE METHYLATION; HUMAN; INTELLECTUAL IMPAIRMENT; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; LUNG CANCER; MELANOMA; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; MOLECULAR PHYLOGENY; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; SET DOMAIN; SOLID TUMOR; SOMATIC MUTATION; TRANSCRIPTION INITIATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; NEOPLASMS; PHYLOGENY;

ANIMALS; DNA-BINDING PROTEINS; DRUG DISCOVERY; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PHYLOGENY; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84959366306     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.89     Document Type: Review

References (145)

1. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 23, 781-783 (2009).
2. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492, (2011).
3. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011).
4. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012).
5. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17, 330-339 (2011).
6. Voigt P, Tee WW, Reinberg D. A double take on bivalent promoters. Genes Dev. 27, 1318-1338 (2013).
7. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and miserased in human cancers. Nat. Rev. Cancer 10, 457-469 (2010).
8. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. Biochim. Biophys. Acta 1815, 75-89 (2011).
9. Kudithipudi S, Jeltsch A. Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim. Biophys. Acta 1846, 366-379 (2014).
10. McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1-22 (2015).
11. Tschiersch B, Hofmann A, Krauss V, Dorn R, Korge G, Reuter G. The protein encoded by the Drosophila positioneffect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO J. 13, 3822-3831 (1994).
12. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6, 227 (2005).
13. Herz HM, Garruss A, Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem. Sci. 38, 621-639. (2013).
14. Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J. Biol. Chem. 286, 7983-7989 (2011).
15. Katoh M. Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: A convergence of proteomics and epigenetics for translational medicine. Expert Rev. Proteomics 12, 317-328 (2015).
16. van Nuland R, Smits AH, Pallaki P, Jansen PW, Vermeulen M, Timmers HT. Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Mol. Cell. Biol. 33, 2067-2077 (2013).
17. De Rubeis S, He X, Goldberg AP et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209-215 (2014).
18. Dong S, Walker MF, Carriero NJ et al. De novo insertions and deletions of predominantly paternal origin are associated with autism spectrum disorder. Cell Rep. 9, 16-23 (2014).
19. Ng SB, Bigham AW, Buckingham KJ et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790-793 (2010).
20. Kleefstra T, Brunner HG, Amiel J et al. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am. J. Hum. Genet. 79, 370-377 (2006).
21. Agha Z, Iqbal Z, Azam M et al. Exome sequencing identifies three novel candidate genes implicated in intellectual disability. PLoS ONE 9, e112687 (2014).
22. Tatton-Brown K, Hanks S, Ruark E et al. Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget 2, 1127-1133 (2011).
23. Douglas J, Hanks S, Temple IK et al. NSD1 mutations are the major cause of Sotos syndrome and occur in some cases of Weaver syndrome but are rare in other overgrowth phenotypes. Am. J. Hum. Genet. 72, 132-143 (2003).
24. Luscan A, Laurendeau I, Malan V et al. Mutations in SETD2 cause a novel overgrowth condition. J. Med. Genet. 51, 512-517 (2014).
25. Baujat G, Rio M, Rossignol S et al. Paradoxical NSD1 mutations in Beckwith-Wiedemann syndrome and 11p15 anomalies in Sotos syndrome. Am. J. Hum. Genet. 74, 715-720 (2004).
26. Sharathkumar A, Kirby M, Freedman M et al. Malignant hematological disorders in children with Wolf-Hirschhorn syndrome. Am. J. Med. Genet. 119A, 194-199 (2003).
27. Palumbo O, Palumbo P, Delvecchio M et al. Microdeletion of 12q24.31: report of a girl with intellectual disability, stereotypies, seizures and facial dysmorphisms. Am. J. Med. Genet. 167A, 438-444 (2015).
28. Kellogg G, Sum J, Wallerstein R. Deletion of 3p25.3 in a patient with intellectual disability and dysmorphic features with further definition of a critical region. Am. J. Med. Genet. 161A, 1405-1408 (2013).
29. Yatsenko SA, Hixson P, Roney EK et al. Human subtelomeric copy number gains suggest a DNA replication mechanism for formation: beyond breakage-fusion-bridge for telomere stabilization. Hum. Genet. 131, 1895-1910 (2012).
30. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43, 875-878 (2011).
31. Liu L, Kimball S, Liu H, Holowatyj A, Yang ZQ. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 6, 2466-2482 (2015).
32. Song Y, Li L, Ou Y et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91-95 (2014).
33. Grasso CS, Wu YM, Robinson DR et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
34. Weirich S, Kudithipudi S, Kycia I, Jeltsch A. Somatic cancer mutations in the MLL3-SET domain alter the catalytic properties of the enzyme. Clin. Epigenetics 7, 36 (2015).
35. Hao C, Wang L, Peng S et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 357, 179-185 (2015).
36. Kanchi KL, Johnson KJ, Lu C et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat. Commun. 5, 3156 (2014).
37. Choi YJ, Oh HR, Choi MR et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. Hum. Pathol. 45, 1674-1681 (2014).
38. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726 (2010).
39. Zingg D, Debbache J, Schaefer SM et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat. Commun. 6, 6051 (2015).
40. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
41. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumorassociated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
42. Majer CR, Jin L, Scott MP et al. A687V EZH2 is a gainof-function mutation found in lymphoma patients. FEBS Lett. 586, 3448-3451 (2012).
43. Jaffe JD, Wang Y, Chan HM et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386-1391 (2013).
44. Zhu X, He F, Zeng H et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 46, 287-293 (2014).
45. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 7, 823-833 (2007).
46. O'Meara E, Stack D, Phelan S et al. Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child. Genes Chromosomes Cancer 53, 991-998 (2014).
47. Tiziana Storlazzi C, Pieri L et al. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. Am. J. Hematol. 89, 438-442 (2014).
48. Jaju RJ, Fidler C, Haas OA et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98, 1264-1267 (2001).
49. Rosati R, La Starza R, Veronese A et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99, 3857-3860 (2002).
50. Stec I, Wright TJ, van Ommen GJ et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum. Mol. Genet. 7, 1071-1082 (1998).
51. Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45, 639-645 (2006).
52. Svedlund J, Barazeghi E, Stalberg P et al. The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors. Endocr. Relat. Cancer 21, 231-239 (2014).
53. Mahmood SF, Gruel N, Nicolle R et al. PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors. Am. J. Pathol. 183, 1634-1644 (2013).
54. Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 70, 8487-8497 (2010).
55. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 34, 280-300 (2014).
56. ClinicalTrials.gov. https://clinicaltrials.gov
57. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6, 846-856 (2006).
58. Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
59. Bhan A, Hussain I, Ansari KI, Bobzean SA, Perrotti LI, Mandal SS. Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol. J. Mol. Biol. 426, 3426-3441 (2014).
60. Iannetti A, Ledoux AC, Tudhope SJ et al. Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence. PLoS Genet. 10, e1004642 (2014).
61. Völkel P, Dupret B, Le Bourhis X, Angrand PO. Diverse involvement of EZH2 in cancer epigenetics. Am. J. Transl. Res. 7, 175-193 (2015).
62. Piper M, Barry G, Harvey TJ et al. NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development. J. Neurosci. 34, 2921-2930 (2014).
63. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23, 5759-5769 (2004).
64. Cao P, Deng Z, Wan M et al. microRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β. Mol. Cancer 9, 108 (2010).
65. Zhao X, Lwin T, Zhang X et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 27, 2341-2350 (2013).
66. Katoh M. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front. Cell Dev. Biol. 2, 61 (2014).
67. Chu CS, Lo PW, Yeh YH et al. O-GlcNAcylation regulates EZH2 protein stability and function. Proc. Natl Acad. Sci. USA 111, 1355-1360 (2014).
68. Yu YL, Chou RH, Shyu WC et al. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol. Med. 5, 531-547 (2013).
69. He A, Shen X, Ma Q et al. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 26, 37-42 (2012).
70. Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc. Natl Acad. Sci. USA 112, 3985-3990 (2015).
71. Kim E, Kim M, Woo DH et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839-852 (2013).
72. Swalm BM, Knutson SK, Warholic NM et al. Reaction coupling between wild-type and disease-associated mutant EZH2. ACS Chem. Biol. 9, 2459-2464 (2014).
73. Shi B, Liang J, Yang X et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 27, 5105-5119 (2007).
74. Viré E, Brenner C, Deplus R et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
75. Lee ST, Li Z, Wu Z et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798-810 (2011).
76. Jung HY, Jun S, Lee M et al. PAF and EZH2 induce Wnt/β-catenin signaling hyperactivation. Mol. Cell 52, 193-205 (2013).
77. Tien CL, Jones A, Wang H, Gerigk M, Nozell S, Chang C. Snail2/Slug cooperates with polycomb repressive complex 2 (PRC2) to regulate neural crest development. Development 142, 722-731 (2015).
78. Xu K, Wu ZJ, Groner AC et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycombindependent. Science 338, 1465-1469 (2012).
79. Abdel-Wahab O, Adli M, LaFave LM et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180-193 (2012).
80. Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY. Inflammationinduced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 15, 580-587 (2014).
81. Dietrich N, Lerdrup M, Landt E et al. REST-mediated recruitment of polycomb repressor complexes in mammalian cells. PLoS Genet. 8, e1002494 (2012).
82. Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al. The polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530 (2007).
83. Schlesinger Y, Straussman R, Keshet I et al. Polycombmediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232-236 (2007).
84. Wee ZN, Li Z, Lee PL, Lee ST, Lim YP, Yu Q. EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. Cell Rep. 8, 204-216 (2014).
85. Gonzalez ME, Moore HM, Li X et al. EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc. Natl Acad. Sci. USA 111, 3098-3103 (2014).
86. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
87. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815-2825 (2006).
88. Crea F, Paolicchi E, Marquez VE, Danesi R. Polycomb genes and cancer: time for clinical application? Crit. Rev. Oncol. Hematol. 83, 184-193 (2012).
89. Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol. Cancer Res. 12, 639-653. (2014).
90. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
91. Knutson SK, Warholic NM, Wigle TJ et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922-7927 (2013).
92. Knutson SK, Kawano S, Minoshima Y et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13, 842-854 (2014).
93. Konze KD, Ma A, Li F et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
94. Xu B, On DM, Ma A et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood 125, 346-357 (2015).
95. Qi W, Chan H, Teng L et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109, 21360-21365 (2012).
96. Garapaty-Rao S, Nasveschuk C, Gagnon A et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem. Biol. 20, 1329-1339 (2013).
97. Kim W, Bird GH, Neff T et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9, 643-650 (2013).
98. Chen H, Gao S, Li J et al. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer. Oncotarget 6 (15), 13049-13059 (2015).
99. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
100. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
101. Jiang X, Lim CZ, Li Z et al. Functional characterization of D9, a novel deazaneplanocin A (DZNep) nalog, in targeting acute myeloid leukemia (AML). PLoS ONE 10, e0122983 (2015).
102. Cheng LL, Itahana Y, Lei ZD et al. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin. Cancer Res. 18, 4201-4212 (2012).
103. Suvà ML, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69, 9211-9218 (2009).
104. Crea F, Hurt EM, Mathews LA et al. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 10, 40 (2011).
105. Kemp CD, Rao M, Xi S et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin. Cancer Res. 18, 77-90 (2012).
106. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
107. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-ofconcept trial. Lancet 376, 235-244 (2010).
108. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proofof-concept trial. Lancet 376, 245-251 (2010).
109. Fece de la Cruz F, Gapp BV, Nijman SM. Synthetic lethal vulnerabilities of cancer. Annu. Rev. Pharmacol. Toxicol. 55, 513-531 (2015).
110. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44, 570-574 (2012).
111. Fillmore CM, Xu C, Desai PT et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520, 239-242 (2015).
112. Wilson BG, Wang X, Shen X et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18, 316-328 (2010).
113. Bitler BG, Aird KM, Garipov A et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1Amutated cancers. Nat. Med. 21, 231-238 (2015).
114. Ribrag V, Soria JC, Reyderman L et al. Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438 as a single agent in patients with advanced solid tumors or B cell lymphoma. Presented at: 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Barcelona, Spain, 18-21 November 2014.
115. GeneCards. www.genecards.org
116. Trotter KW, Archer TK. The BRG1 transcriptional coregulator. Nucl. Recept. Signal. 6, e004 (2008).
117. Leung JY, Nevins JR. E2F6 associates with BRG1 in transcriptional regulation. PLoS ONE 7, e47967 (2012).
118. Sánchez-Tilló E, Lázaro A, Torrent R et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29, 3490-4500 (2010).
119. Gaugler T, Klei L, Sanders SJ et al. Most genetic risk for autism resides with common variation. Nat. Genet. 46, 881-885 (2014).
120. Do R, Stitziel NO, Won HH et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 518, 102-106 (2015).
121. Crea F, Fornaro L, Paolicchi E et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 23, 1207-1213 (2012).
122. Ma ZB, Guo GH, Niu Q, Shi N. Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population. Int. J. Mol. Sci. 15, 12688-12697 (2014).
123. Zhou Y, Du WD, Wu Q et al. EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population. Mol. Carcinog. 53, 589-597 (2014).
124. Yu YL, Su KJ, Hsieh MJ et al. Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features. PLoS ONE 9, e93635 (2014).
125. Van Rechem C, Whetstine JR. Examining the impact of gene variants on histone lysine methylation. Biochim. Biophys. Acta 1839, 1463-1476 (2014).
126. Gibaja V, Shen F, Harari J et al. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene doi:10.1038/onc.2015.114 (2015) (Epub ahead of print).
127. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J. 26, 752-763 (2007).
128. Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 328, 198-206 (2013).
129. DuPage M, Chopra G, Quiros J et al. The chromatinmodifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42, 227-238 (2015).
130. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
131. Kim SH, Joshi K, Ezhilarasan R et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Rep. 4, 226-238 (2015).
132. Katona BW, Liu Y, Ma A, Jin J, Hua X. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biol. Ther. 15, 1677-1687 (2014).
133. Riquelme E, Suraokar M, Behrens C et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinumbased and VEGFR-2-targeted therapy. Clin. Cancer Res. 20, 3849-3861 (2014).
134. Momparler RL, Côté S, Momparler LF, Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin. Epigenetics 6, 19 (2014).
135. Gelsi-Boyer V, Trouplin V, Adélaïde J et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145, 788-800 (2009).
136. Kwon SJ, Lee SK, Na J et al. Targeting BRG1 chromatin remodeler via its bromodomain for enhanced tumor cell radiosensitivity in vitro and in vivo. Mol. Cancer Ther. 14, 597-607 (2015).
137. Katoh M. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks. Int. J. Mol. Med. 32, 763-767 (2013).
138. Sashida G, Harada H, Matsui H et al. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat. Commun. 5, 4177 (2014).
139. Delgado-Olguín P, Huang Y, Li X et al. Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat. Genet. 44, 343-347 (2012).
140. Zhang J, Ji F, Liu Y et al. Ezh2 regulates adult hippocampal neurogenesis and memory. J. Neurosci. 34, 5184-5199 (2014).
141. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 132, 344-362 (2008).
142. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 12, 715-723 (2011).
143. Hartman ZC, Poage GM, den Hollander P et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73, 3470-3480 (2013).
144. Datta De D, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J. Gastroenterol. 21, 2883-2895 (2015).
145. Hayashi Y, Tsujii M, Wang J et al. CagA mediates epigenetic regulation to attenuate let-7 expression in Helicobacter pylori-related carcinogenesis. Gut 62, 1536-1546 (2013).